Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Strata Skin Sciences (SSKN) Risk Analysis

Public companies are required to disclose risks that can affect the business and impact the stock. These disclosures are known as “Risk Factors”. Companies disclose these risks in their yearly (Form 10-K), quarterly earnings (Form 10-Q), or “foreign private issuer” reports (Form 20-F). Risk factors show the challenges a company faces. Investors can consider the worst-case scenarios before making an investment. TipRanks’ Risk Analysis categorizes risks based on proprietary classification algorithms and machine learning. Strata Skin Sciences disclosed 45 risk factors in its most recent earnings report. Strata Skin Sciences reported the most risks in the “Finance & Corporate” category.

Risk Overview Q4, 2025

Source: the company's latest filing for the period ended Dec 31, 2025, filed Mar 25, 2026

Risk Distribution
45Risks
Sector Avg.Finance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Risk Change Over Time

Strata Skin Sciences disclosed risks per quarterNo. of Risks363840424446Q3Q12024Q2Q3Q4Q12025Q2Q3Q4Showing: Q4, 2025
Risks removedRisks addedRisks changedStrata Skin Sciences Risk Factors
New Risk (3)
  • Share Price & Shareholder Rights - Risk 1
    Our shares of common stock have been delisted from The Nasdaq Capital Market which could result in, among other things, a decline in the price of our common stock and less liquidity for holders of shares of our common stock.

    Our common stock is no longer listed on The Nasdaq Capital Market. We are now traded OTC and the ability to find a ready market to purchase and sell our shares is severely limited thereby.

Read and Evaluate the RiskReserved for Ultimate MembersUpgrade
Macro & Political (1)

Risk Highlights Q4, 2025

Main Risk Category
Finance & Corporate
With 12 Risks
Number of Disclosed Risks
45
+2
From last report
S&P 500 Average: 32
Recent Changes
3Risks added
0Risks removed
2Risks changed
Since Dec 2025
Number of Risk Changed
2
+2
From last report
S&P 500 Average: 1

Risk Word Cloud

our failure to respond to rapid changes in technology and other applications in the medical devices industry or the development of a cure for skin conditions treated by our products could make our treatment system obsolete.make our treatment system obsoleteour market acceptance in international markets requires regulatory approvals from foreign governments and may depend on third party reimbursement of participants' cost.international markets requires regulatory approvalour shares of common stock have been delisted from the nasdaq capital market which could result in, among other things, a decline in the price of our common stock and less liquidity for holders of shares of our common stock.price of our common stockwe may not be able to maintain an uninterrupted supply of the gases used to power our lasers, as the russia-ukraine war has disrupted supplies of rare gases.disrupted supplies of rare gasesour laser treatments of psoriasis, vitiligo, atopic dermatitis and leukoderma and/or any of our future products or services may fail to gain market acceptance or be impacted by competitive products, services or therapies which could adversely affect our competitive position.our laser treatments of psoriasiswe may become subject to claims of infringement or misappropriation of the intellectual property rights of others, which could prohibit us from shipping affected products, require us to obtain licenses from third parties or to develop non-infringing alternatives, and subject us to substantial monetary damages and injunctive relief. our patents may also be subject to challenge on validity grounds, and our patent applications may be rejected.to develop non-infringing alternativeswe actively employ social media as part of our marketing strategy, which could give rise to regulatory violations, liability, breaches of data security or reputational damage.give rise to regulatory violationsour shares of common stock have been delisted from the nasdaq capital market which could result in, among other things, a decline in the price of our common stock and less liquidity for holders of shares of our common stock.our shares of common stockour failure to obtain or maintain necessary fda clearances and approvals, or to maintain continued clearances, or equivalents thereof in the u.s. and relevant foreign markets, could hurt our ability to distribute and market our products.hurt our ability to distributepublic health epidemics or pandemics may affect our ability to develop, market and sell our products, disrupt regulatory activities or have other adverse effects on our business and operations. in addition, public health epidemics or pandemics may adversely impact economies worldwide, which could result in adverse effects on our business, operations and prospects.affect our ability to develop

Risk Factors Full Breakdown - Total Risks 45

Share Price & Shareholder Rights4 | 8.9%
  • Share Price & Shareholder Rights - Risk 1
    Our charter documents and Delaware law may inhibit a takeover that stockholders consider favorable and could also limit the market price of our stock.

    Provisions of our restated certificate of incorporation and bylaws and applicable provisions of Delaware law may make it more difficult for or prevent a third party from acquiring control of us without the approval of our Board of Directors. These provisions: - limit who may call a special meeting of stockholders;- establish advance notice requirements for nominations for election to our Board of Directors or for proposing matters that can be acted upon at stockholder meetings;- do not permit cumulative voting in the election of our directors, which would otherwise permit less than a majority of stockholders to elect directors;- prohibit stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of our stockholders; and - provide our Board of Directors the ability to designate the terms of and issue a new series of preferred stock without stockholder approval. In addition, Section 203 of the Delaware General Corporation Law generally limits our ability to engage in any business combination with certain persons who own 15% or more of our outstanding voting stock or any of our associates or affiliates who at any time in the past three years have owned 15% or more of our outstanding voting stock. In connection with the financing in May 2018, our Board of Directors exempted AGP SPVI, L.P. from the application of this provision in connection with its investment. These provisions may have the effect of entrenching our management team and may deprive you of the opportunity to sell your shares to potential acquirers at a premium over prevailing prices. This potential inability to obtain a control premium could reduce the price of our common stock.

  • Share Price & Shareholder Rights - Risk 2
    Our stock price may be volatile, meaning purchasers of our common stock could incur substantial losses.

    Our common stock is no longer listed on The Nasdaq Capital Market and currently trades on the OTC. Our stock price has been and is likely to continue to be volatile without a ready market in which to trade our shares. The stock market in general and the market for medical technology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The following factors, in addition to other risk factors described in this section and general market and economic conditions, may have a significant impact on the market price of our common stock: - failure of any of our products to achieve or continue to have commercial success;- the timing of regulatory approval for our future products;- adverse regulatory determinations with respect to our existing products;- results of our research and development efforts and our clinical trials;- the announcement of new products or product enhancements by us or our competitors;- regulatory developments in the U.S. and foreign countries;- our ability to manufacture our products to commercial standards;- developments concerning our clinical collaborators, suppliers or marketing partners;- changes in financial estimates or recommendations by securities analysts;- public concern over our products;- developments or disputes concerning patents or other intellectual property rights;- product liability claims and litigation against us or our competitors;- the departure of key personnel;- the strength of our balance sheet and any perceived need to raise additional funds;- variations in our financial results from expected financial results or those of companies that are perceived to be similar to us;- changes in the structure of third-party reimbursement in the U.S. and other countries;- changes in accounting principles or practices;- the lack of current public information regarding our business;- general economic, industry and market conditions; and - future sales of our common stock. A decline in the market price of our common stock could cause you to lose some or all of your investment, limit your ability to sell your shares of stock and may adversely impact our ability to attract and retain employees and raise capital. In addition, stockholders have, and may in the future, initiate securities class action lawsuits if the market price of our stock drops significantly. Whether or not meritorious, litigation brought against us could result in substantial costs and could divert the time and attention of our management. Our insurance to cover claims of this sort may not be adequate.

  • Share Price & Shareholder Rights - Risk 3
    Your percentage ownership will be further diluted in the future.

    Your percentage ownership in our common stock will be diluted in the future because of equity awards that we expect will be granted to our directors, officers and employees. Our Equity Incentive Plan provides for the grant of equity-based awards, including restricted stock, restricted stock units, stock options, stock appreciation rights and other equity-based awards to our directors, officers and other employees, advisors and consultants. In connection with the Senior Term Facility, we issued a warrant to MidCap to purchase 80,000 shares of our common stock, with an exercise price of $8.80 per share. As a result of shares sold or issued under the circumstances described above, your percentage ownership in our common stock will be diluted in the future.

  • Share Price & Shareholder Rights - Risk 4Changed
    Our shares of common stock have been delisted from The Nasdaq Capital Market which could result in, among other things, a decline in the price of our common stock and less liquidity for holders of shares of our common stock.

    Our common stock is no longer listed on The Nasdaq Capital Market. We are now traded OTC and the ability to find a ready market to purchase and sell our shares is severely limited thereby.

Accounting & Financial Operations2 | 4.4%
Debt & Financing4 | 8.9%
Corporate Activity and Growth2 | 4.4%

See a full breakdown of risk according to category and subcategory. The list starts with the category with the most risk. Click on subcategories to read relevant extracts from the most recent report.

FAQ

What are “Risk Factors”?
Risk factors are any situations or occurrences that could make investing in a company risky. The Securities and Exchange Commission (SEC) requires that publicly traded companies disclose their most significant risk factors. This is so that potential investors can consider any risks before they make an investment. They also offer companies protection, as a company can use risk factors as liability protection. This could happen if a company underperforms and investors take legal action as a result. It is worth noting that smaller companies, that is those with a public float of under $75 million on the last business day, do not have to include risk factors in their 10-K and 10-Q forms, although some may choose to do so.
How do companies disclose their risk factors?
Publicly traded companies initially disclose their risk factors to the SEC through their S-1 filings as part of the IPO process. Additionally, companies must provide a complete list of risk factors in their Annual Reports (Form 10-K) or (Form 20-F) for “foreign private issuers”. Quarterly Reports also include a section on risk factors (Form 10-Q) where companies are only required to update any changes since the previous report. According to the SEC, risk factors should be reported concisely, logically and in “plain English” so investors can understand them.
How can I use TipRanks risk factors in my stock research?
Use the Risk Factors tab to get data about the risk factors of any company in which you are considering investing. You can easily see the most significant risks a company is facing. Additionally, you can find out which risk factors a company has added, removed or adjusted since its previous disclosure. You can also see how a company’s risk factors compare to others in its sector. Without reading company reports or participating in conference calls, you would most likely not have access to this sort of information, which is usually not included in press releases or other public announcements. A simplified analysis of risk factors is unique to TipRanks.
What are all the risk factor categories?
TipRanks has identified 6 major categories of risk factors and a number of subcategories for each. You can see how these categories are broken down in the list below. 1. Financial & Corporate Accounting & Financial Operations - risks related to accounting loss, value of intangible assets, financial statements, value of intangible assets, financial reporting, estimates, guidance, company profitability, dividends, fluctuating results. Share Price & Shareholder Rights – risks related to things that impact share prices and the rights of shareholders, including analyst ratings, major shareholder activity, trade volatility, liquidity of shares, anti-takeover provisions, international listing, dual listing. Debt & Financing – risks related to debt, funding, financing and interest rates, financial investments. Corporate Activity and Growth – risks related to restructuring, M&As, joint ventures, execution of corporate strategy, strategic alliances. 2. Legal & Regulatory Litigation and Legal Liabilities – risks related to litigation/ lawsuits against the company. Regulation – risks related to compliance, GDPR, and new legislation. Environmental / Social – risks related to environmental regulation and to data privacy. Taxation & Government Incentives – risks related to taxation and changes in government incentives. 3. Production Costs – risks related to costs of production including commodity prices, future contracts, inventory. Supply Chain – risks related to the company’s suppliers. Manufacturing – risks related to the company’s manufacturing process including product quality and product recalls. Human Capital – risks related to recruitment, training and retention of key employees, employee relationships & unions labor disputes, pension, and post retirement benefits, medical, health and welfare benefits, employee misconduct, employee litigation. 4. Technology & Innovation Innovation / R&D – risks related to innovation and new product development. Technology – risks related to the company’s reliance on technology. Cyber Security – risks related to securing the company’s digital assets and from cyber attacks. Trade Secrets & Patents – risks related to the company’s ability to protect its intellectual property and to infringement claims against the company as well as piracy and unlicensed copying. 5. Ability to Sell Demand – risks related to the demand of the company’s goods and services including seasonality, reliance on key customers. Competition – risks related to the company’s competition including substitutes. Sales & Marketing – risks related to sales, marketing, and distribution channels, pricing, and market penetration. Brand & Reputation – risks related to the company’s brand and reputation. 6. Macro & Political Economy & Political Environment – risks related to changes in economic and political conditions. Natural and Human Disruptions – risks related to catastrophes, floods, storms, terror, earthquakes, coronavirus pandemic/COVID-19. International Operations – risks related to the global nature of the company. Capital Markets – risks related to exchange rates and trade, cryptocurrency.